Membrane proteins (MPs) are the gatekeepers of cells and play an important role in a variety of cellular functions such as material transport, signal transduction, and cell-to-cell recognition (Figure 1). Abnormal functions of MPs often lead to the occurrence of diseases. Therefore, MPs account for more than 60% of all the current FDA-approved drug targets and 90% of the antibody drug targets.
Figure 1: Membrane proteins play important roles in a variety of cellular functions.
Despite the significance, drug discovery against membrane protein is still challenging, because it is difficult to find a good antigen for the generation of antibody against membrane proteins especially the multispan membrane proteins. Membrane proteins tend to lose the functions when removed from the membrane. A good antigen is particularly critical for the development of monoclonal antibodies (mAbs) with therapeutic properties. Therefore, membrane proteins have been considered as “undruggable” targets in pharmaceutical companies.Figure 2: DIMA’s solutions for the full-length multipass transmembrane proteins
Table 1: Antigens for membrane protein antibody drug discovery
Plasma membrane-coated nanoparticles (MNPs) have been used in various applications, including delivery of therapeutic agents and induction of immune responses et al. Unlike the conventional strategies, MNPs directly leverage intact and natural functions of cell membranes, and show high biocompatibility, specificity, and low side effects. DIMA biotech developed an optimized MNPs platform for the full-length membrane protein productions using membrane coating technology and HEK293 based expression platform. The high-purity plasma membrane-coated nanoparticles were produced by extrusion after membrane extraction from the host HEK293 cells containing the overexpressed target proteins (Figure 3).
Figure 3:Membrane Nanoparticles (MNP) for the preparation of the full-length multipass transmembrane proteins
A. Negative Control 1: CCR8 full length membrane nanoparticles samples were stained only with Goat anti-human lgG 488 secondary antibody.
B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-CCR8 antibody (BME100063) at 2 μg/mL, followed by Goat anti-human IgG 488 secondary antibody.
C. Negative Control 3: CCR8 full length membrane nanoparticles samples were stained with anti-Claudin 18.2 antibody (an irrelevant antibody) at 2 μg/mL, followed by Goat anti-human IgG 488 secondary antibody.
D. CCR8 full length membrane nanoparticles samples were stained with anti-CCR8 antibody (BME100063) at 2 μg/mL, followed by Goat anti-human IgG 488jsecondary antibody.
Western blot of CCR8 membrane nanoparticles (MNPs)
ELISA plates were pre-coated with 0.5ug/per well purified human Claudin 18.2 VLP. Serial diluted Anti-Claudin18.2 monoclonal antibody (Zolbetuximab biosililar; IMAB362) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for IMAB362 binding with Claudin18.2 is 15.37ng/ml.
Negative Control 1: Claudin18.2 VLP samples were stained only with Goat anti-human IgG Fc-PE secondary antibody.
Negative Control 2: Control VLP samples were stained with anti-Claudin18.2 antibody(Zolbetuximab biosililar; IMAB362)at 1ug/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.
Negative Control 3: Claudin18.2 VLP samples were stained with anti-BCMA antibody(an irrelevant antibody)at 1ug/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.
Claudin18.2 VLP samples were stained with anti-Claudin18.2 antibody(Zolbetuximab biosililar; IMAB362)at 1ug/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.
Figure 5: Exosomes (EXO) for the preparation of the full-length multipass transmembrane proteins
Human GPRC5D full length protein-EXO
Figure 1. ELISA plates were pre-coated with 0.5 μg/per well purified human CD24 exosome. Serial diluted Anti-CD24 monoclonal antibody solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 is 69.61 ng/ml.
Figure 2. Nanoparticle Tracking Analysis of CD24 exosomes
Figure 3. TEM image of CD24 exosomes
Figure 6: Detergent for the preparation of the full-length multipass transmembrane proteins
Human Claudin-6 full-length protein(with 1% DDM)
Figure 7: Synthetic Nanodisc for the preparation of the full-length multipass transmembrane proteins